Article

Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.

LuEsther T. Mertz Retinal Research Center/Manhattan Eye, Ear & Throat Hospital and Vitreous-Retina-Macula Consultants of New York, New York, USA.
Retina (impact factor: 2.81). 27(4):451-7. DOI:10.1097/IAE.0b013e318030ea80 pp.451-7
Source: PubMed

ABSTRACT To evaluate the short-term visual acuity and anatomic responses after intravitreal bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous proliferation (RAP).
The authors conducted a retrospective review of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal bevacizumab (1.25 mg) during a 3-month period. Complete ocular examination was performed at baseline and follow-up visits. Interval data were analyzed statistically at 1 and 3 months follow-up.
Twenty-three eyes of 23 patients underwent intravitreal bevacizumab treatment. The mean age of patients was 81.1 years, median baseline visual acuity of treated eyes was 20/80 (range 20/25-20/800), and mean baseline central macular thickness was 335 mum (optical coherence tomography was available for 22 eyes). Nine eyes had retinal pigment epithelial detachments (PEDs) at baseline. At 1-month follow-up, the median acuity improved to 20/60 (range 20/30-20/400) (P < 0.001), mean central macular thickness decreased to 202 microm (P < 0.001), and PED was present in only 2 eyes (P = 0.016). Seven of 23 eyes at 1 month (30.4%) had improved visual acuity, defined as halving of the visual angle, and no eyes had worse acuity, defined as doubling of the visual angle. Of the 17 eyes available for 3-month follow-up, 5 eyes (29.4%) had better visual acuity, 1 eye (5.9%) had worse acuity, and the remaining 11 (64.7%) had the same acuity. The median visual acuity at month 3 was 20/60 (range 20/25-20/400). There were no thromboembolic phenomena, endophthalmitis cases, retinal detachments, or any other adverse events.
Treatment of RAP with intravitreal bevacizumab during this retrospective review resulted in a significant decrease in macular thickness and improvement or stabilization of visual acuity. Further long-term investigation is warranted given the promising short-term results.

0 0
 · 
0 Bookmarks
 · 
29 Views
  • Source
    Article: Periodontal disease in a patient receiving Bevacizumab: a case report.
    Dorothy M Gujral, Sanjeev Bhattacharyya, Peter Hargreaves, Gary W Middleton
    [show abstract] [hide abstract]
    ABSTRACT: Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported before. We report a case of a forty-three year old woman who developed periodontitis whilst receiving bevacizumab for lung cancer. The periodontal disease remained stable on discontinuation of the drug. Further investigations are needed to determine the mechanism for bevacizumab-induced periodontal disease.
    Journal of Medical Case Reports 02/2008; 2:47.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1 month
 
1-month follow-up
 
17 eyes available
 
3 months follow-up
 
3-month follow-up
 
3-month period
 
Complete ocular examination
 
follow-up visits
 
intravitreal bevacizumab treatment
 
median baseline visual acuity
 
median visual acuity
 
month 3
 
optical coherence tomography
 
promising short-term results
 
recurrent RAP
 
remaining 11
 
retinal angiomatous proliferation
 
short-term visual acuity
 
significant decrease
 
thromboembolic phenomena
 

Catherine B Meyerle